Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$36.2 million.

  • Gossamer Bio's Free Cash Flow fell 12.91% to -$36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.5 million, marking a year-over-year decrease of 11134.02%. This contributed to the annual value of -$3.5 million for FY2024, which is 97.82% up from last year.
  • Latest data reveals that Gossamer Bio reported Free Cash Flow of -$36.2 million as of Q3 2025, which was up 23.24% from -$47.1 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Free Cash Flow registered a high of $116.3 million during Q2 2024, and its lowest value of -$53.6 million during Q1 2022.
  • Its 3-year average for Free Cash Flow is -$26.0 million, with a median of -$36.2 million in 2025.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 404.17% in 2024, then slumped by 140.49% in 2025.
  • Over the past 4 years, Gossamer Bio's Free Cash Flow (Quarterly) stood at -$47.8 million in 2022, then spiked by 30.12% to -$33.4 million in 2023, then decreased by 6.15% to -$35.5 million in 2024, then decreased by 12.91% to -$36.2 million in 2025.
  • Its last three reported values are -$36.2 million in Q3 2025, -$47.1 million for Q2 2025, and -$39.8 million during Q1 2025.